<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20220712055438N5</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-11-04</date_registration>
      <primary_sponsor>Mashhad University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of Chitosan Dressing and Routine Dressing on Cesarean Wound Healing, Pain, and Infection</public_title>
      <acronym></acronym>
      <scientific_title>Evaluating the Efficacy of an Innovative Chitosan Dressing Compared to Routine Hospital Dressing on Wound Healing, Postoperative Pain, and Surgical Site Infection Following Cesarean Section: A Randomized Controlled Clinical Trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-11-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>68</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>https://irct.ir/trial/94539</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Eligible participants will be allocated to either the intervention or control group with a 1:1 allocation ratio using permuted block randomization with variable block sizes of 4 and 6. The random allocation sequence will be generated by an independent statistical consultant (not involved in clinical intervention or outcome assessment) using computer-generated random sequences to maintain group balance and prevent allocation sequence predictability, Blinding description: This study is designed as a single-blind randomized controlled trial. Because the dressing is applied onto the surgical incision in the operating room immediately following Cesarean section while the mother is under regional or general anesthesia, the participant remains completely blinded to the allocated intervention (chitosan dressing versus routine hospital dressing). Due to physical and visual distinctions between the two dressing types, blinding of the healthcare provider and the outcome assessor is not feasible.</study_design>
      <phase>2-3</phase>
      <hc_freetext>Surgical wound healing, postoperative pain, and surgical site infection (SSI) following cesarean section.</hc_freetext>
      <i_freetext>Intervention group: mmediately following skin closure in the operating room, the surgical incision is covered with an innovative chitosan nanofiber dressing..</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
De-identified individual participant data (IPD), the study protocol, and the statistical analysis plan will be available 6 months following the publication of the final trial results. Data will be shared upon reasonable academic request for scientific research or meta-analyses, subject to ethics committee approval and agreement of the corresponding author via official correspondence.

When:
Beginning 6 months and ending 3 years following article publication.

To whom:
Academic researchers and investigators in reproductive health and wound care fields for research purposes and meta-analyses (upon approval of the corresponding author).

Conditions:
Exclusively for scientific research, systematic reviews, and meta-analyses, provided that data confidentiality is maintained, commercial use is avoided, and proper citation of the main article is ensured.

Where to obtain:
Corresponding author (Research Deputy / Department of Midwifery, Mashhad University of Medical Sciences), via official email request.

How to obtain:
Submission of a formal written request and brief proposal to the corresponding author, evaluation of the request by the research team and ethics committee within a specified timeframe (max one month), and upon approval, secure transfer of de-identified data via email.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Sedigheh Abdollahpour</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Vakilabad Blvd, Shahid Bahonar Blvd, University Campus, Kharazmi Building, School of Nursing and Midwifery</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9177943760</zip>
        <telephone>+98 51 3841 7660</telephone>
        <email>abdollahpourts2@yahoo.com</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Sedigheh Abdollahpour</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Vakilabad Blvd, Shahid Bahonar Blvd, University Campus, Kharazmi Building, School of Nursing and Midwifery</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9177943760</zip>
        <telephone>+98 51 3841 7660</telephone>
        <email>abdollahpourts2@yahoo.com</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Provision of written informed consent to participate in the study.Maternal age between 18 and 40 years.Gestational age between 37 completed weeks and 41 weeks (based on first-trimester ultrasound or confirmed LMP).Primiparous women undergoing elective Cesarean section with a transverse lower uterine segment incision (Pfannenstiel incision).Body Mass Index (BMI) less than 35 kg/m² at the time of hospital admission.Absence of underlying systemic medical conditions known to impair wound healing (e.g., pre-gestational or gestational diabetes, autoimmune disorders, chronic kidney or liver disease, and coagulopathies).No history of receiving immunosuppressive agents, systemic corticosteroids, or chemotherapy within the preceding three months.</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>40 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>O86.0 O90.</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>عوارض جراحی مامایی و زایمان (شامل عفونت زخم جراحی مامایی و اختلال ترمیم زخم سزارین)</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: mmediately following skin closure in the operating room, the surgical incision is covered with an innovative chitosan nanofiber dressing.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Wound Healing. Timepoint: on days 2, 7, 14, and 30 post-surgery. Method of measurement: Assessed using the REEDA scale.</prim_outcome>
      <prim_outcome>Postoperative Pain. Timepoint: on days 2, 7, 14, and 30 post-surgery. Method of measurement: Visual Analog Scale (VAS).</prim_outcome>
      <prim_outcome>Surgical Site Infection (SSI). Timepoint: on days 2, 7, 14, and 30 post-surgery. Method of measurement: Clinical evaluation of infection signs based on CDC criteria.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Mashhad University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2026-11-03</approval_date>
        <contact_name>Ethics committee of Mashhad University of Medical Sciences</contact_name>
        <contact_address>Vakilabad mashhad Razavi Khorasan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
